STOCK TITAN

STEMTECH (STEK) Stock News, Aug-Nov 2022

STEK OTC

Stemtech Corporation (STEK) develops and distributes stem cell nutrition and stemceutical wellness products, including plant-based nutritional supplements, skin care and oral care products. Its updates commonly cover product availability, inventory funding, the Stemtech BioSciences e-commerce retail channel, and the company's network marketing model built around Independent Business Partners.

Company news also addresses scientific and advisory appointments, regulatory alignment for global wellness products, and international distribution initiatives through subsidiaries and joint ventures in markets such as India and the Gulf Cooperation Council region. Stemtech operates as a Nevada public company that became publicly traded in 2021 after continuing operations under new leadership in 2018.

Rhea-AI Summary

Stemtech Corporation (OTCQB:STEK) announced enhancements to its AdvanceOffice mobile app, designed to improve efficiency for Independent Business Partners (IBPs). Launched in September 2022, the app provides vital tools for IBPs to promote Stemtech's products. Upcoming features include business analytics reports and CRM integration to streamline performance tracking. The company aims to drive growth through technological innovation in its direct sales model, continuing its legacy of pioneering stem cell nutrition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.86%
Tags
none
-
Rhea-AI Summary

Stemtech Corporation (OTCQB:STEK) announced significant advancements in the stem cell nutrition sector, emphasizing the rising investment in R&D, projected to reach $4.5 billion by 2027. President John W. Meyer highlighted the launch of new stemceuticals focusing on health and wellness, with a skincare product debuting at the December Cancun event. Tully & Holland noted a growing consumer focus on health post-pandemic, while CEO Cliff Layton projected revolutionary products from their R&D division, Life Factor Research. Founded in 2018, Stemtech continues to innovate in the stem cell market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
none
-
Rhea-AI Summary

Stemtech Corporation (OTCQB: STEK) has finalized an acquisition agreement with Life Factor Research, enhancing its capabilities in research, development, and product formulation in the nutraceutical sector. This strategic move is expected to enable Stemtech to introduce innovative health products targeting anti-aging and longevity. Both companies express optimism about the vast potential this partnership brings, particularly given Life Factor Research's proprietary technologies and formulations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
Rhea-AI Summary

Stemtech Corporation (OTCQB: STEK) has announced the formation of a new Board of Directors for Stemtech Malaysia Sdn. Bhd. The new board includes Charles S. Arnold, CEO, David E. Price, Corporation Counsel, and John W. Meyer, who was elected Chairman. This restructuring aims to leverage market opportunities in Malaysia and enhance growth potential. Stemtech specializes in stem cell nutrition and operates under the direct sales distribution model, focusing on patent-protected products that aid in adult stem cell release and circulation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary

Stemtech Corporation (OTCQB: STEK), a leader in stem cell nutrition, announced its invitation to present at the Roth Capital Healthcare Opportunities Conference in New York City on October 6. CEO Charles S. Arnold expressed pride in being part of this prestigious event, highlighting the company's focus on stemceuticals that enhance immune function and promote health and wellness.

Founded in 2005, Stemtech specializes in innovative nutraceutical products, which are plant-based and manufactured under stringent quality standards. The company aims to boost the body's adult stem cells for improved quality of life.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.56%
Tags
conferences
-
Rhea-AI Summary

Stemtech Corporation (OTCQB: STEK), a leader in nutraceuticals, announced the launch of new stem cell skincare products. CEO John W. Meyer expressed excitement about expanding their offerings at the upcoming Cancun Incentive Meeting in December. The global skincare market is projected to grow significantly, and Stemtech aims to leverage its scientific advancements in stem cell technology to capture market share. The company believes this product line will provide growth and revenue opportunities for its Independent Business Partners and enhance the overall customer experience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.96%
Tags
none
Rhea-AI Summary

Stemtech Corporation (OTCQB: STEK) announced the Go-Live date for its Stemtech Advance Office on September 19, 2022. Developed with VERB Technology Company, Inc. (NASDAQ: VERB), the platform aims to enhance communication and business capabilities for Independent Business Partners (IBPs). President John W. Meyer highlighted the software's potential to improve recruiting and retention efforts, leveraging interactive video-based sales applications. Stemtech, known for its patent-protected nutraceutical products supporting adult stem cell release, is positioned to increase its market momentum through this strategic partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.5%
Tags
none
-
Rhea-AI Summary

Stemtech Corporation (OTCQB: STEK) announces the appointment of Professor Dr. Bankole Johnson to its Life Sciences Advisory Board. Dr. Johnson, a highly regarded figure in the medical field, is expected to provide valuable insights as Stemtech focuses on enhancing health through science. His extensive background includes roles at the University of Virginia and the University of Maryland, along with recognition for his work in addiction treatment. This addition aligns with Stemtech's strategy to advance its proprietary health products and strengthen its leadership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.34%
Tags
management
-
Rhea-AI Summary

Stemtech Corporation (OTCQB: STEK) has issued a Letter of Intent to acquire Life Factor Research, enhancing its R&D capabilities in stem cell nutrition and related products. This acquisition is expected to position Stemtech at the forefront of advanced stem cell technology, allowing quicker market penetration of innovative health products. The collaboration aims to cater to an expanding market with a focus on anti-aging and longevity. The CEO of Life Factor Research highlights the potential for redefining market standards through this partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.23%
Tags
Rhea-AI Summary

Stemtech Corporation (OTCQB: STEK), a leader in nutraceuticals, has announced its sponsorship of the ADVENT EXPO. This event aims to connect millions of viewers globally in a virtual metaverse setting, promoting Stemtech's anti-aging and plant-based stem cell nutrition products. President John W. Meyer emphasized the exposure opportunities provided by the Expo, which combines health and financial aspects for potential consumers. Stemtech's products, which are patented and all-natural, are produced under stringent manufacturing practices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.78%
Tags
none

FAQ

What is the current stock price of STEMTECH (STEK)?

The current stock price of STEMTECH (STEK) is $0.000001 as of September 28, 2026.

What is the market cap of STEMTECH (STEK)?

The market cap of STEMTECH (STEK) is approximately 299.7K.